# US 2025/0154100 A1 · Crystalline forms of psilacetin

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0154100 A1
- Document ID: US20250154100A1
- Status: Published application
- Kind: A1
- Application number: 18/958,489
- Filed: 2024-11-25
- Published: 2025-05-15
- Earliest claimed: 2020-03-23
- Assignees: Caamtech, Inc.
- Applicants: Caamtech, Inc.
- Inventors: Andrew R. CHADEAYNE
- Web page: https://patentgrep.com/patent/US20250154100A1

## CPC

- C07D 209/16: Tryptamines
- A61K 31/4045: Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
- C07B 2200/13: Crystalline forms, e.g. polymorphs
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

Crystalline forms of 4-acetoxy-N,N-dimethyltryptamine (psilacetin), compositions containing that crystalline form, and their methods of use are disclosed. The crystalline forms of 4-acetoxy-N,N-dimethyltryptamine (psilacetin) according to the disclosure include crystalline 4-acetoxy-N,N-dimethyltryptammonium hydrofumarate, the fumarate salt of psilacetin, and/or crystalline bis(4-acetoxy-N,N-dimethyltryptammonium) fumarate, and pharmaceutical compositions containing a crystalline form of psilacetin.

## Claims

### Claim 1

A method of preventing or treating schizophrenia comprising the step of:
administering to a subject in need thereof a therapeutically effective amount of crystalline 4-acetoxy-N,N-dimethyltryptammonium hydrofumarate.

### Claim 2 (depends on 1)

The method of claim 1, wherein the crystalline 4-acetoxy-N,N-dimethyltryptammonium hydrofumarate is characterized by:
a monoclinic, P21lc crystal system space group at a temperature of about 296 K,
unit cell dimensions a=13.023 (1) Å, b=7.4823 (6) Å, c=19.102 (2) Å, α=90°, β=103.251 (3)°,
and γ=90° at a temperature of about 296 K;
an x-ray powder diffraction pattern substantially similar to FIG. 4; or
an x-ray powder diffraction pattern characterized by peaks at 7.0, 13.0 and 21.8° 2θ±0.2° 2θ.

### Claim 3 (depends on 1)

The method of claim 1, wherein the method comprises administering the therapeutically effective amount of crystalline 4-acetoxy-N,N-dimethyltryptammonium hydrofumarate and an excipient.

### Claim 4 (depends on 1)

The method of claim 1, wherein the method comprises administering the therapeutically effective amount of crystalline 4-acetoxy-N,N-dimethyltryptammonium hydrofumarate and a second component selected from (a) a purified psilocybin derivative, (b) one or two purified cannabinoids, and (c) a purified terpene.

### Claim 5

A method of preventing or treating a brain disorder comprising the step of:
administering to a subject in need thereof a therapeutically effective amount of crystalline bis(4-acetoxy-N,N-dimethyltryptammonium) fumarate or crystalline 4-acetoxy-N,N-dimethyltryptammonium hydrofumarate.

### Claim 6 (depends on 5)

The method of claim 5, wherein the brain disorder is selected from the group consisting of Huntington's disease, Alzheimer's disease, dementia, and Parkinson's disease.

### Claim 7 (depends on 5)

The method of claim 5, wherein crystalline bis(4-acetoxy-N,N-dimethyltryptammonium) fumarate is administered.

### Claim 8 (depends on 7)

The method of claim 7, wherein the crystalline bis(4-acetoxy-N,N-dimethyltryptammonium) fumarate is characterized by:
a triclinic, P1 crystal system space group at a temperature of about 200 K;
unit cell dimensions a=8.3965 (13) Å, b=8.9879 (14) Å, c=12.0126 (16) Å, α=101.730 (5)°, β=100.818 (5)°, and γ=112.463 (5)° at a temperature of about 200 K;
an x-ray powder diffraction pattern substantially similar to FIG. 8; or
an x-ray powder diffraction pattern characterized by peaks at 7.9, 18.4 and 24.0° 2θ±0.2° 2θ.

### Claim 9 (depends on 7)

The method of claim 7, wherein the method comprises administering the therapeutically effective amount of crystalline bis(4-acetoxy-N,N-dimethyltryptammonium) fumarate and an excipient.

### Claim 10 (depends on 7)

The method of claim 7, wherein the method comprises administering the therapeutically effective amount of crystalline bis(4-acetoxy-N,N-dimethyltryptammonium) fumarate and a second component selected from (a) a purified psilocybin derivative, (b) one or two purified cannabinoids, and (c) a purified terpene.

### Claim 11 (depends on 5)

The method of claim 5, wherein the crystalline 4-acetoxy-N,N-dimethyltryptammonium hydrofumarate is administered.

### Claim 12 (depends on 11)

The method of claim 11, wherein the crystalline 4-acetoxy-N,N-dimethyltryptammonium hydrofumarate is characterized by:
a monoclinic, P21lc crystal system space group at a temperature of about 296 K,
unit cell dimensions a=13.023 (1) Å, b=7.4823 (6) Å, c=19.102 (2) Å, α=90°, β=103.251 (3)°,
and γ=90° at a temperature of about 296 K;
an x-ray powder diffraction pattern substantially similar to FIG. 4; or
an x-ray powder diffraction pattern characterized by peaks at 7.0, 13.0 and 21.8° 2θ±0.2° 2θ.

### Claim 13 (depends on 11)

The method of claim 11, wherein the method comprises administering the therapeutically effective amount of crystalline 4-acetoxy-N,N-dimethyltryptammonium hydrofumarate and an excipient.

### Claim 14 (depends on 11)

The method of claim 11, wherein the method comprises administering the therapeutically effective amount of crystalline 4-acetoxy-N,N-dimethyltryptammonium hydrofumarate and a second component selected from (a) a purified psilocybin derivative, (b) one or two purified cannabinoids, and (c) a purified terpene.
